This opportunity involves the preclinical development of Cap-dependent endonuclease inhibitors (CENi) as broad-spectrum antiviral therapeutics. The scope includes selecting lead candidates through in vitro and in vivo efficacy studies, as well as compound characterization and optimization. Research support is required for work with viruses requiring biosafety level 4 (BSL-4) containment. The services will be performed at the Naval Medical Research Command in Fort Detrick, MD. The project will be conducted over a 36-month period.